Table 4.
Multivariate analysis of prognostic factors on survival in 2190 Danish patients with newly diagnosed symptomatic multiple myeloma
| Variable | Univariate analysis | Multivariable analysis |
|---|---|---|
| Hazard ratio (95% CI) | Hazard ratio (95% CI) | |
| Charlson Comorbidity Index | ||
| 0 | 1 (ref) | 1 (ref) |
| 1 | 1.7 (1.5–2.0) | 1.5 (1.2–1.8) |
| 2 | 1.3 (1.1–1.5) | 1.3 (1.0–1.5) |
| ≥3 | 2.0 (1.7–2.4) | 1.7 (1.4–2.1) |
| Age (>65 years) | 2.5 (2.2–2.9) | 2.2 (1.9–2.6) |
| Gender (male) | 1.0 (0.9–1.1) | – |
| International staging system (ISS) | ||
| 1 | 1 (ref) | 1 (ref) |
| 2 | 1.8 (1.5–2.2) | 1.6 (1.3–1.9) |
| 3 | 2.9 (2.4–3.4) | 1.9 (1.6–2.4) |
| Increased serum lactate dehydrogenase level | 1.5 (1.3–1.7) | 1.3 (1.1–1.5) |
| Increased serum creatinine level | 1.8 (1.6–2.0) | 1.2 (1.0–1.4) |
| Increased serum C‐reactive protein level | 1.6 (1.5–1.8) | 1.2 (1.1–1.4) |
| IgA M‐component | 1.2 (1.0–1.4) | 1.3 (1.1–1.5) |
| WHO Performance status (0–1 vs. 2–4) | 2.0 (1.8–2.2) | 1.7 (1.5–2.0) |
Comorbidity assessed by Charlson Comorbidity Index based on diagnoses registered from 10 years to 1 month prior to myeloma diagnosis in the Danish National Patient Registry.